MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma
Michael A. Milhollen(Millennium Engineering and Integration (United States)), Peter G. Smith(Kenya Medical Research Institute), Mark Manfredi(Millennium Engineering and Integration (United States)), Allison Berger(Takeda (United States)), Lawrence R. Dick(Millennium Engineering and Integration (United States)), Erik Koenig(Millennium Engineering and Integration (United States)), Louis M. Staudt(National Cancer Institute), Jennifer Adams-Duffy(Millennium Engineering and Integration (United States)), Joseph B. Bolen(Bristol-Myers Squibb (United States)), Mark Rolfe(Unknown), Teresa A. Soucy(Millennium Engineering and Integration (United States)), Steven Langston(Millennium Engineering and Integration (United States)), Usha Narayanan(Millennium Engineering and Integration (United States)), James Garnsey(Millennium Engineering and Integration (United States)), Jie Yu(KU Leuven), Julie Zhang(Millennium Engineering and Integration (United States)), Tary Traore(Millennium Engineering and Integration (United States)), Michael P. Thomas(Millennium Engineering and Integration (United States)), Lenny Dang(Millennium Engineering and Integration (United States))
Cited by 323
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k